Zentalis Pharmaceuticals, Inc. ZNTL
1.72 USD +0.01 (+0.58%)
At closeNov 6, 2026, 7:02 PM EST
1.73 +0.01 +0.58%
After hours · Nov 6, 7:02 PM ET
1.71 Day range 1.83
1.28 52-week range 6.61
- YTD
- +27.41%
- 1 year
- +32.31%
Financial health
Altman Z-Score
-9.09 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
Rating
C-1 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 2
- P/E 1
- P/B 3
Valuation
P/E -0.7×
FY 2018 5y median -3.4× FY 2025
P/S 0.0×
FY 2018 5y median 0.0× FY 2025
P/B 0.4×
FY 2018 5y median 2.3× FY 2025
P/FCF -0.8×
FY 2018 5y median -4.8× FY 2025
EV/EBITDA -0.7×
FY 2018 5y median -4.1× FY 2025
EV/Sales 0.0×
FY 2018 5y median 0.0× FY 2025
FCF Yield -129.1%
FY 2018 5y median -21.0% FY 2025
Profitability
Gross Margin 0.0%
FY 2018 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2018 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2018 5y median 0.0% FY 2025
ROE -63.4%
FY 2018 5y median -54.6% FY 2025
ROIC -59.6%
FY 2018 5y median -50.3% FY 2025
ROA -47.4%
FY 2018 5y median -42.8% FY 2025
Growth (YoY)
Revenue -100.0%
FY 2018 FY 2025
Operating Income 20.1%
FY 2018 FY 2025
EPS (diluted) 18.0%
FY 2018 FY 2025
Free Cash Flow 26.8%
FY 2018 FY 2025
Financial Health
Current Ratio 6.9×
FY 2018 5y median 7.3× FY 2025
Quick Ratio 6.9×
FY 2018 5y median 7.3× FY 2025
Debt / Equity 0.2×
FY 2018 5y median 0.1× FY 2025
Net Debt / EBITDA -0.0×
FY 2018 5y median -0.0× FY 2025
Interest Coverage 0.0×
FY 2018 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2018 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2018 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31